25823-52-3

Basic information

• Product Name: 2,5,6,7-tetrahydro-3H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-one
• CAS NO: 25823-52-3
• Molecular Weight: 212.251
• Mol File: 25823-52-3.mol

Chemical Properties

• CAS DataBase Reference: 2,5,6,7-tetrahydro-3H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-one(CAS DataBase Reference)
• NIST Chemistry Reference: 2,5,6,7-tetrahydro-3H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-one(25823-52-3)
• EPA Substance Registry System: 2,5,6,7-tetrahydro-3H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-one(25823-52-3)

Safety Data

• Hazardous Substances Data: 25823-52-3(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Industry:
2,5,6,7-tetrahydro-3H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-one is used as a building block for the synthesis of bioactive compounds due to its unique molecular structure and potential to contribute to the development of new therapeutic agents.
Used in Neurological Disorders Treatment:
THBP is used as a therapeutic agent for the treatment of neurological disorders, leveraging its pharmacological properties to address various conditions affecting the nervous system.
Used in Psychiatric Conditions Treatment:
In the psychiatric field, 2,5,6,7-tetrahydro-3H-benzo[6,7]cyclohepta[1,2-c]pyridazin-3-one is utilized as a potential treatment for psychiatric conditions, offering new avenues for managing mental health disorders through its unique chemical interactions.

Upstream product

• 826-73-3 1-Benzosuberone 
• 6742-32-1 2-(5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-6-yl)acetic acid 
• 25742-81-8 ethyl 2-(5-oxo-6,7,8,9-tetrahydro-5H-benzo[7]annulene-6-yl)acetate 
• 127-68-4 sodium 3-nitrobenzenesulfonate 
• 25742-87-4 2,4,4a,5,6,7-hexahydro-3H-benzo<6,7>cyclohepta<1,2-c>pyridazin-3-one 
• 298-12-4 Glyoxilic acid 

Downstream Products

• 25823-53-4 3-chloro-2,5,6,7-tetrahydro-3H-benzo[6,7]cyclohepta[1,2-c]pyridazine 
• 802598-74-9 3-hydrazino-6,7-dihydro-5H-benzo[6,7]cyclohepta[1,2-c]pyridazine 

Relevant articles and documents

AXL INHIBITORS FOR USE IN COMBINATION THERAPY FOR PREVENTING, TREATING OR MANAGING METASTATIC CANCER

This invention is directed to methods of preventing, treating or managing cancer, preferably metastatic cancer, in a patient. The methods comprise administering an effective amount of an Axl inhibitor in combination with the administration of an effective

POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS

Polycyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases

POLYCYCLIC ARYL SUBSTITUTED TRIAZOLES AND POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS

Polycyclic aryl and polycyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases or conditions associated with Axl catalytic activity are also disclosed.

BICYCLIC ARYL AND BICYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS

Bicyclic aryl substituted triazoles or heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the com

POLYCYCLIC HETEROARYL SUBSTITUTED TRIAZOLES USEFUL AS AXL INHIBITORS

Polycyclic heteroaryl substituted triazoles and pharmaceutical compositions containing the compounds are disclosed as being useful in inhibiting the activity of the receptor protein tyrosine kinase Axl. Methods of using the compounds in treating diseases

Design, synthesis, and structure-activity relationships of a series of 3-[2-(1-benzylpiperidin-4-yl)ethylamino]pyridazine derivatives as acetylcholinesterase inhibitors

Starting from the 3-[2-(1-benzylpiperidin-4-yl)ethylamino]-6-phenylpyridazine 1, we performed the design, the synthesis, and the structure-activity relationships of a series of pyridazine analogues acting as AChE inhibitors. Structural modifications were achieved on four different parts of compound 1 and led to the following observations: (i) introduction of a lipophilic environment in the C-5 position of the pyridazine ring is favorable for the AChE-inhibitory activity and the AChE/BuChE selectivity; (ii) substitution and various replacements of the C-6 phenyl group are possible and led to equivalent or slightly more active derivatives; (iii) isosteric replacements or modifications of the benzylpiperidine moiety are detrimental to the activity. Among all derivatives prepared, the indenopyridazine derivative 4g was found to be the more potent inhibitor with an IC50 of 10 nM on electric eel AChE. Compared to compound 1, this represents a 12-fold increase in potency. Moreover, 3-[2-(1-benzylpiperidin-4-yl)ethylamino]-5-methyl-6-phenylpyridazine 4c, which showed an IC50 of 21 nM, is 100-times more selective for human AChE (human BuChE/AChE ratio of 24) than the reference compound tacrine.